Over thirty years ago, a five-year-old boy lost his vision after a regular eye exam failed to spot a retinal detachment. 

His father, Douglas Anderson, made it his mission to revolutionize retinal imaging for eye care professionals. And in 1992 when Optos was founded, his goal was met with the availability of a patient-friendly device that can capture an ultra-widefield (UWF™) high-resolution retinal image. And today, these devices are still the only devices that, in a single-capture, image approximately 82% or 200◦ of the retina.  

At Optos, research and development are at our core and where we continue to invest. This ongoing focus most recently includes the first UWF, CE-marked AI-based technology which enables the early detection and management of diabetic retinopathy, which is, globally, a leading cause of blindness among adults. 

Rob Kennedy, CEO of Optos:

“We are proud of what Optos has achieved over the past three decades. We have remained true to Douglas’s core purpose of improving patient outcomes by providing the best imaging technology and so reduce the risk of sight loss. 

In pursuit of this purpose, we pioneered the only single capture UWF retinal imaging, and now more than 22,000 optomap devices are in use worldwide. We have delivered significant growth, continued to develop our technology, and ultimately enabled our customers to help save the sight of their patients. 

I want to thank the entire team at Optos for their innovation and hard work over the last 30 years. It’s this dedication and commitment that has helped shape Optos to become the business it is today and we look forward to continuing to push the boundaries in support of our customers and their patients.”